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Synopsis 
Genetic variants in complement pathways, lipid metabolism and angiogenesis increase 
neovascular age-related macular degeneration risk in the Indian setting. Certain key risk variants 
are more common in Indian ancestry compared with European. 
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Abstract   
Background/Aims: There are limited data from India on genetic variants influencing late age-
related macular degeneration (AMD). We have previously reported associations from a 
population-based study in India (INDEYE) of early AMD and Single Nucleotide Polymorphisms 
(SNPs) in ARMS2/HTRA1 and no association with CFH, C2 or CFB. Late AMD cases were too 
few for meaningful analyses. We aimed to investigate SNPs for late AMD through case 
enrichment and extend loci for early AMD. 
Methods: Fundus images of late AMD hospital cases were independently graded by the 
modified Wisconsin AMD grading scheme. In total 510 cases with late AMD (14 Geographic 
Atrophy and 496 neovascular (nvAMD), 1876 with early AMD and 1176 with no signs of AMD 
underwent genotyping for selected SNPs. We investigated genotype and per-allele additive 
associations (Odds Ratios (OR) and 95% Confidence Interval (CI) with nvAMD or early AMD. 
Bonferroni adjusted p-values are presented.  
Results: We found associations with nvAMD for CFH Y402H variant (rs1061170), OR=1.99, 
95% CI 1.67- 2.37, p=10-6, ARMS2 (rs10490924), OR=2.94, 2.45 - 3.52, p=10-9, C2 (rs547154), 
OR=0.67, 0.53-0.85 p=0.01, ABCA1 (rs1883025), OR=0.77, 0.65-0.92, p=0.04 and a SNP near 
VEGFA (rs4711751) OR=0.64, 0.54-0.77, p=10-3. We found no associations of TLR3 
(rs3775291), CFD (rs3826945), FRK (rs1999930) or LIPC (rs10468017) or APOE ε4 alleles 
with nvAMD or early AMD nor between early AMD and rs1883025 or rs4711751.  
Conclusions: The major genetic determinants of nvAMD risk in India are similar to those in 
other ancestries whilst findings for early AMD suggest potential differences in the 
pathophysiology of AMD development.  
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Introduction 
Genetic risk variants for late age related macular degeneration (AMD) have been identified, and 
further confirmed in Genome Wide Association studies (GWAS), the majority in studies of 
European ancestry.1 There is less information on late AMD genetic risk in India, with most data 
coming from one patient/control cohort.2-4 We have previously reported genetic results from a 
large population-based study of people aged 60 and over in  India (INDEYE) for early AMD 
with variants in complement factor H (CFH), factor B (CFB), component 2 (C2),  
ARMS2/HTRA1.5 Late AMD cases were too few for meaningful analyses. In the present paper 
we present results for late AMD based on an enriched sample, and for other genetic loci with 
early AMD.   
 
Materials and Methods 
INDEYE was conducted between 2005 and 2007 in two locations in south (Tamil Nadu) and 
north (Haryana) India. The study methods including sampling and recruitment, blood collection, 
ophthalmological examination and AMD grading along with results on the prevalence of early 
and late AMD have been published. 6 In the present study, we recruited additional cases of late 
AMD between 2009 and 2011 from the hospitals that participated in the INDEYE study (All 
India Institute of Medical Sciences (AIIMS) Delhi, Aravind Eye Hospital Pondicherry, Tamil 
Nadu) and additionally from Aravind Eye Hospital Madurai, Tamil Nadu.  We aimed to achieve 
600 late AMD cases plus two population controls per case to detect the two-fold per allele 
association of Y402H CFH (rs1061170) reported in a meta-analysis of primarily European 
ancestry7 at 90% power and alpha <0.001. Initial eligibility criteria were age 60 years and over, 
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Indian descent and a diagnosis of late AMD by the retinal ophthalmologists. Controls were 
participants in the INDEYE study with no signs of early or late AMD in either eye. 
In both INDEYE and clinic participants, informed written consent was obtained prior to 
enrolment. If the participant was illiterate the information sheet was read out aloud in the 
presence of a local witness, and a thumb impression of the participant signified assent. The study 
complied with the Declaration of Helsinki and ethics approval was received from the Indian 
Council for Medical Research, the Research Ethics Committees of AIIMS, Aravind Eye 
Hospital, London School of Hygiene and Tropical Medicine and Queens University Belfast.  
Full details of the method of ascertainment of AMD in the population study have previously 
been published.6. In brief two 35degree stereo fundus photographs of each eye were taken and 
graded at Queens University Belfast (QUB) using the modified Wisconsin Age-Related 
Maculopathy Grading System.8 Each eye was classified into 5 mutually exclusive grades, Grade 
1-soft distinct drusen (63 m) only or pigmentary irregularities only; Grade 2 - soft indistinct 
(125m) or reticular drusen only or soft distinct drusen (≥ 63µm) with pigmentary 
irregularities; Grade 3 -(soft indistinct (≥ 125µm) or reticular drusen ) with pigmentary 
irregularities;   Grade 4 - either Neovascular AMD (nvAMD) (presence of any of the following: 
serous or haemorrhagic retinal or retinal pigment epithelial detachment, subretinal neovascular 
membrane, periretinal fibrous scar) or Geographic Atrophy, GA (well-demarcated area of retinal 
pigment atrophy with visible choroidal vessels). Fundus images of cases recruited from hospital 
clinics were sent to QUB (color photographs, optical coherence tomograms (OCT)) and graded 
as above. In all graded images, GA and nvAMD present in the same eye were categorized as 
nvAMD. Images that showed no signs of any features of early or late AMD were categorized as 
having no AMD.  
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DNA extraction and genotyping 
Genomic DNA was extracted from peripheral blood leukocytes using Quiagen kits. SNPs were 
genotyped using TaqMan assays in an ABI 7900 real-time PCR. We limited our study to genes 
in biological pathways relevant to AMD pathogenesis including complement activation (CFH, 
CFB, CFD)  and deposition (toll like receptors (TLR 3, 4,7), lipid metabolism (ABCA1, APOE, 
CETP, LIPC) or the degradation of the extracellular matrix (TIMP3).9  We investigated two 
SNPs on chromosome 6, previously reported to be associated with late AMD 10 (LOC107986598 
rs4711751  located near VEGFA  and FRK rs1999930 near COL10A1). We included  SNPs in 
ARMS2/HTRA1 due to  their demonstrated  importance in many studies11 and recent evidence for 
an ARMS2 role in surface complement regulation.12 We tested for departures from Hardy 
Weinberg equilibrium (HWE) in controls and excluded any SNPs with a p value ≤ 0.05. We used 
logistic regression in Stata14 (StataCorp LP) to examine associations of (i) genotype and (ii) per- 
allele additive models adjusted for age, sex, and centre. We present additionally Bonferroni 
adjusted p-values for the number of independent SNPs tested. We created APOE alleles from the 
SNPs rs429358 (T/C) and rs7412(C/T) resulting in three alleles: ε2 (TT), ε3 (TC) and ε4 (CC).  
Analyses of APOE alleles used ε3 as the reference group. 
 
Results 
The prevalence of early and late AMD in the INDEYE population study has been published.6  
There were 1986 cases of early AMD (1686 Grade1, 289 Grade 2, 11 Grade 3), 53 of late AMD 
(44 nvAMD 9 GA) and 1228 population controls with no signs of AMD in either eye.  Hospital 
retinal clinics recruited 533 cases based on ophthalmologists’ diagnoses. After exclusion of 
participants without confirmed late AMD or missing blood samples (Figure), 496 nvAMD cases, 
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1876 early AMD and 1176 controls were available for analysis. We did not investigate GA 
because of small numbers (n=14). The mean age in years (SD) was 65.3 (5.4) in population 
controls, early AMD, 67.0 (6.1) and nvAMD, 70.7 (6.9). The number and proportion of women 
was 600 (51%), 915 (49%) and 179 (36%) respectively. Two SNPs (rs4986790 TLR4/ TLR7, 
rs9621532 TIMP3) failed HWE. HWE and MAFs for remaining SNPs are shown in Table 1. We 
also present MAFs for European and Indian ancestry from the 1000 genome study 
https://www.ncbi.nlm.nih.gov/snp accessed December 5 2016.  Control frequencies of APOE 
alleles were ε3 (0.73), ε2 (0.09) and ε4 (0.18). 
We found additive associations with nvAMD for Y402H, (rs1061170), HTRA1 (rs2672598), 
ARMS2 (rs10490924, rs10490923) CFB (rs438999, rs547154), ABCA1 (rs1883025) and SNP 
rs4711751 close to VEGFA (Table 2). We found no associations with TLR3 (rs3775291), CFD 
(rs3826945), FRK (rs1999930) or LIPC (rs10468017). There was no association between APOE 
ε4 and nvAMD, OR= 0.72, 95% CI (0.52,1.01).  
We combined Grades 2 and 3 of early AMD due to the small numbers of Grade 3. Subsequently 
we combined all grades of early AMD (1 to 3) because our preliminary analyses revealed no 
differences in genetic associations for these early stages. There were no associations with early 
AMD and any of the SNPs (Table 3) or with APOE ε4, OR= 0.88, 95% CI (0.73,1.01).  
 
Discussion 
CFH and ARMS2 /HTRA1 have been identified in numerous studies in European 1 11 and East 
Asian ancestry13 as the most important genes  for late AMD risk with effect sizes around  2.5 and 
3 per-allele respectively 1 7 11 and the top two variants at GWAS significance.1  Our effect sizes 
of 2 for the C allele of Y402H variant of CFH (rs1061170) and 3 for ARMS2 T allele 
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(rs10490924) are consistent with these findings and add to the limited evidence for India.2 3 The 
MAF of rs1061170 is lower in East Asian (< 0.10) compared to European ancestry (0.3)7 and 
higher for rs10490924 (0.4), almost twice that in European ancestry.9  Our MAFs for rs1061170 
(0.32) and rs10490924 (0.32) concur with those for  South Asians in the 1000 Genome Study 
(Table 1) and other sources in India. 2,3,14  It appears that rs1061170 allele frequencies in Indian 
ancestry are closer to European than East Asian and intermediate between European and East 
Asian for rs10490924.  
We found associations with SNPs in other genes established predominantly in European ancestry 
including C2, SKIV2L, ABCA1 and in a SNP (rs4711751) in an uncharacterized gene 
LOC107986598 close to VEGFA.1 We found a reduced risk with the T allele of ABCA1 
(rs1883025) but not with CETP or LIPC. A meta-analysis of European ancestry studies found 
APOE ε4 haplotype was associated with  a 30% lower risk of nvAMD 15; we observed a similar 
effect  but with wide confidence intervals. 
We found no association with early AMD and any of the variants reported in Table 3. We have 
previously reported results for early AMD and found no association with Y402H (rs1061170), C2 
(rs547154), SKIVL (rs43899).5  ARMS2/HTRA1 variants (rs10490924 and rs2672598) were 
associated with early AMD, the OR per allele was 1.22, 95% CI (1.13-1.33), p<0.0001 and 1.12 
(1.02-1.23), p=0.02 respectively.5 A  GWAS meta-analysis of 4089 early AMD cases, the 
majority of European ancestry, found associations between SNPs in CFH and ARMS2/HTRA1 
but with smaller effect sizes  than those reported for late AMD.16 Analyses by Asian ancestry 
found no association with any CFH SNP whereas ARMS2 (rs10490924) was associated with an 
OR of 1.18 (1.07, 1.13), similar to our study, compared to 1.43 (1.34, 1.54) for European 
ancestry.  The lower prevalence of early AMD in Asia17  and India6  may, in part, be explained 
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by the apparently lesser role of genetic variants compared to studies in European ancestry but 
caution is warranted due to the paucity of genetic studies of early AMD in Indian and East Asian 
ancestry. 
 
Limitations 
Although we did not attain the 600 planned cases, we confirmed the per-allele two fold risk of 
rs1061170 and nvAMD hypothesized for the sample size estimates.   We had low power to 
investigate variants with low MAFs (compared to European ancestry) such as FRK, LIPC or to 
identify smaller effects. The majority of late AMD cases were of nvAMD phenotype similar to 
studies in East Asia18 and we could not investigate genetic associations with Geographic 
Atrophy. It is possible we misclassified population cases of late AMD. We had confirmatory 
OCTs in 89% of clinic late AMD cases but the population-based study used color images only.   
 
Conclusions 
Our findings suggest the major genetic determinants of neovascular AMD risk in India are 
similar to those in other populations whilst findings for early AMD suggest potential differences 
in the pathophysiology of AMD development.   
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Table 1. Single Nucleotide Polymorphisms, Minor Allele Frequency (MAF) and test for Hardy Weinberg Equilibrium and 
corresponding reported MAF in the 1000 genomes project in South Asian and European populations 
Chromosome Gene SNP1 Major/Minor 
Alleles 
 
HWE2 MAF3 MAF EUR4 MAF SAS5 
1 Y402H rs1061170 T/C 0.6854 0.323 0.362 0.287 
4 TLR3 rs3775291 C/T 0.9347 0.235 0.324 0.263 
6 C2 rs547154 C/A 0.3813 0.187 0.089 0.156 
6 SKIV2L rs438999 A/G 0.6932 0.183 0.089 0.148 
6 LOC1079865986 rs4711751 T/C 1 0.423 0.487 0.330 
6 FRK rs1999930 C/T 0.3957 0.075 0.281 0.052 
9 ABCA1 rs1883025 C/T 0.0797 0.432 0.240 0.413 
10 ARMS2 rs10490923 G/A 0.7299 0.149 0.130 0.148 
10 ARMS2 rs10490924 G/T 0.1953 0.319 0.195 0.343 
10 HTRA1 rs2672598 T/C7 0.2969 0.524 0.499 0.464 
15 LIPASE rs10468017 C/T 0.9195 0.176 0.283 0.184 
16 CETP rs3764261 C/A 0.0737 0.295 0.292 0.321 
19 APOE rs429358 T/C 1 0.097 0.155 0.087 
19 APOE rs7412 C/T 0.5232 0.050 0.063 0.044 
19 CFD rs3826945 T/C 0.8424 0.344 0.313 0.334 
 
1 Single Nucleotide Polymorphisms (SNP) 
2 p value for tests for departure from Hardy Weinberg Equilibrium (HWE) in controls 
3Minor Allele Frequency (MAF) in controls 
4 Minor Allele Frequency (MAF) from 1000 genome study for European ancestry available in https://www.ncbi.nlm.nih.gov/snp 
5 Minor Allele Frequency (MAF from 1000 genome study for South Asian ancestry available in https://www.ncbi.nlm.nih.gov/snp 
6 SNP located near VEGFA 
7 Minor allele considered as C for comparison with other studies 
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Table 2.  Association of neovascular age-related macular degeneration with Single Nucleotide Polymorphisms 
   1 versus 0 copies of  
minor allele 
2 versus 0 copies of 
minor allele 
Additive per minor allele 
Gene SNP1 
 
Major/Minor 
Alleles 
 
Odds 
Ratio2 
95% CI3 Odds 
Ratio2 
95% CI3 Odds 
Ratio2 
95% CI3 p P4 
Y402H rs1061170  T/C 1.72 1.31 -  2.28 4.13 2.91 -  5.87 1.99 1.67 – 2.37 10-7 10-6 
TLR3 rs3775291  C/T 1.18 0.92 -  1.51 0.88 0.51 -  1.53 1.06 0.87 -  1.30 0.545  
C2 rs547154   C/A 0.62 0.47 - 0 .82 0. 64 0.29 -  1.43 0.67 0.53 -  0 .85 0.001 0.01 
SKIV2L rs438999 A/G 0.63 0.47 -  0.83 0.50 0.21 -  1.22 0.65 0.50 -  0.83 0.001 0.01 
LOC107986598 rs4711751 T/C 0.35 0.27 -  0.46 0.65 0.45 -  0 .94 0.64 0.54 -  0 .77 10-4 10-3 
FRK rs1999930 C/T 0.93 0.64 -  1.34 5.94 1.17 - 30.10 1.05 0.74 -  1.49 0.777  
ABCA1 rs1883025 C/T 0.81 0.61 -  1.07 0.58 0.41 -  0.83 0.77 0.65 -  0.92 0.003 0.04 
ARMS2 rs10490923 G/A 0.49 0.35 -  0.67 0.85 0.33 -  2.17 0.57 0.43 -  0.75 10-3 0.04 
ARMS2 rs10490924 G/T 1.86 1.37 -  2.51 8.73 6.11 - 12.48 2.94 2.45 -  3.52 10-10 10-9 
HTRA1 rs2672598 T/C 1.53 1.01 -  2.32 5.42 3.58 –  8.21 2.67 2.19 -  3.25 10-9 10-8 
LIPC rs10468017 C/T 1.13 0.87 -  1.47 1.12 0.56 -   2.23 1.11 0.89 -  1.37 0.370  
CETP rs3764261 C/A 1.27 0.98 -  1.64 1.26 0.82 -   1.91 1.17 0.98 -  1.41 0.087  
APOE rs429358 T/C 0.82 0.60 -  1.14 NC5  NC5    
APOE rs7412 C/T 0.87 0.58 -  1.32 NC5  NC5    
CFD rs3826945 T/C 1.02 0.79 -  1.31 1.05 0.70 - 1.58 1.02 0.85 -  1.23 0.820  
 
1Single Nucleotide Polymorphisms (SNP) 
2 adjusted for age, sex, centre 
3 95% Confidence interval 
4 Bonferroni adjusted p-value for 13 per -allele tests 
5 Not calculated, no cases with 2 copies of minor allele  
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Table 3 Association of early age-related macular degeneration with Single Nucleotide Polymorphisms  
 
  1 versus 0 copies of minor allele 2 versus 0 copies of minor allele Additive per allele  
Gene SNP1 Odds 
Ratio1 
95% CI2 p Odds Ratio1 95% CI2 p Odds 
Ratio1 
95% CI2 p 
TLR3 rs3775291 1.01 0.86-1.20 0.868 1.13 0.83-1.54 0.425 1.04 0.92-1.16 0.520 
LOC107986598 rs4711751 0.95 0.78-1.14 0.558 0.91 0.69-1.20 0.502 0.95 0.84-1.08 0.452 
FRK rs1999930 0.83 0.66-1.05 0.117 1.63 0.39-6.77 0.498 0.88 0.69-1.12 0.285 
ABCA1 rs1883025 0.96 0.79-1.17 0.698 0.96 0.77-1.19 0.726 0.98 0.88-1.09 0.699 
LIPASE rs10468017 0.97 0.82-1.14 0.677 1.08 0.67-1.75 0.744 0.99 0.85-1.15 0.913 
CETP rs3764261 1.08 0.91-1.28 0.365 1.10 0.90-1.33 0.339 1.06 0.96-1.17 0.228 
APOE rs429358 0.93 0.77-1.12 0.454 0.80 0.35-1.84 0.594 0.93 0.77-1.10 0.380 
APOE rs7412 0.97 0.74-1.27 0.826 1.38 0.42-4.55 0.594 1.00 0.79-1.27 0.994 
CFD rs3826945 1.02 0.88-1.20 0.758 1.10 0.87-1.39 0.399 1.04 0.94-1.15 0.416 
 
1 Single Nucleotide Polymorphisms (SNP) 
2 adjusted for age, sex, centre 
3 95% Confidence interval 
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Figure Legend 
Flowchart of hospital case recruitment and population cases and controls 
